Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth

The persistence of a reservoir of latently infected CD4 T cells remains one of the major obstacles to cure HIV. Numerous strategies are being explored to eliminate this reservoir. To translate these efforts into clinical trials, there is a strong need for validated biomarkers that can monitor the re...

Full description

Saved in:
Bibliographic Details
Published in:PLoS pathogens 2016-03, Vol.12 (3), p.e1005472-e1005472
Main Authors: Kiselinova, Maja, De Spiegelaere, Ward, Buzon, Maria Jose, Malatinkova, Eva, Lichterfeld, Mathias, Vandekerckhove, Linos
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
Adult
AIDS
Biological markers
Biology and Life Sciences
Biomarkers
Clinical trials
Cohort Studies
Deoxyribonucleic acid
Diagnosis
Disease Reservoirs - virology
DNA
DNA, Viral - analysis
DNA, Viral - isolation & purification
Drug therapy
Experiments
Female
Funding
Health aspects
Highly active antiretroviral therapy
HIV
HIV Infections - virology
HIV-1 - genetics
HIV-1 - growth & development
Human immunodeficiency virus
Human immunodeficiency virus 1
Humans
Linear Models
Lymphocytes
Male
Medicine and Health Sciences
Middle Aged
Patients
Regression analysis
Research and Analysis Methods
RNA, Viral - analysis
RNA, Viral - isolation & purification
Shipments
Viral Load
Virus Integration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The persistence of a reservoir of latently infected CD4 T cells remains one of the major obstacles to cure HIV. Numerous strategies are being explored to eliminate this reservoir. To translate these efforts into clinical trials, there is a strong need for validated biomarkers that can monitor the reservoir over time in vivo. A comprehensive study was designed to evaluate and compare potential HIV-1 reservoir biomarkers. A cohort of 25 patients, treated with suppressive antiretroviral therapy was sampled at three time points, with median of 2.5 years (IQR: 2.4-2.6) between time point 1 and 2; and median of 31 days (IQR: 28-36) between time point 2 and 3. Patients were median of 6 years (IQR: 3-12) on ART, and plasma viral load (
ISSN:1553-7374
1553-7366
1553-7374
DOI:10.1371/journal.ppat.1005472